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PAGE 5: ABSTRACT 
 
Body composition after kidney transplantation is linked to glucose metabolism, and impaired 
glucose metabolism is associated with increased risk of cardiovascular events and death. One 
year after transplantation we examined 150 patients for new-onset diabetes performing 
OGTTs and body composition measurements including visceral adipose tissue (VAT) content 
from dual-energy X-ray absorptiometry scans. We found that glucose metabolism was 
generally improved and that the levels of VAT and percentage VAT of total body fat mass 
(VAT%totBFM) were lowest in those with normal glucose tolerance and highest in those with 
post transplant diabetes mellitus. In a multivariable linear regression analysis 87.4% of the 
variability in fasting glucose concentration was explained by insulin resistance 
(p<0.001,HOMA-IR index), beta cell function (p<0.001,HOMA-beta), VAT%totBFM (p=0.007) 
and BMI (p=0.015) (total model p<0.001), while insulin resistance (p<0.001) and beta cell 
function (p<0.001) explained 31.9% of the variability in 2-hour glucose concentration in a 
multivariable model (total model p<0.001). VAT was associated with glucose metabolism to 
a larger degree than BMI. In conclusion, VAT is associated with hyperglycemia one year after 
kidney transplantation, and insulin resistance and beta cell function estimates are the most 












Post transplant diabetes mellitus (PTDM) resembles type 2 diabetes, but may also be 
considered a separate entity with noninfectious inflammation and use of diabetogenic 
immunosuppressive drugs as additional provoking factors. After transplantation some degree 
of inflammation is unavoidable and use of immunosuppressive agents with negative impact 
on glucose metabolism is essential to preserve graft function and avoid rejection. Actually, 
choice of immunosuppressive therapy has been reported to explain up to 74% of the incidence 
of PTDM1, urging the importance of close monitoring and individualization of medication. 
However, this does not invalidate the importance of modifiable risk factors such as energy 
intake exceeding energy expenditure and obesity.  
Body composition and in particular abdominal obesity is linked to the development of 
type 2 diabetes2-6 and also abnormal glucose metabolism after kidney transplantation7. Post 
transplant weight gain is associated with reduced graft function and graft survival8,9 and 
decreased long-term survival10. Both impaired glucose tolerance (IGT) and PTDM are 
associated with adverse long-term outcomes including increased risk of cardiovascular events 
and death in kidney transplant recipients11-14.  
Visceral fat (VAT) is considered a marker of whole-body dysfunctional adipose 
tissue,15 and is associated with insulin resistance independently of BMI16,17. VAT may be an 
interesting link between metabolic and cardiovascular disease. Until recently, VAT has been 
examined in patients by computed tomography (CT) scans, but with high radiation, low 
availability and significant costs, CT is obviously not suitable for screening of patients in a 
clinical setting. However, assessment of VAT has lately become feasible using novel 
validated software applied on standard dual-energy X-ray absorptiometry (DXA) scans18.  
We have previously presented a cross-sectional study on patients in a stable phase 8-
10 weeks after kidney transplantation, showing a close association between visceral fat and 
glucose metabolism. Abdominal obesity and VAT were more strongly associated with 
impaired fasting glucose (IFG), IGT and PTDM than body mass index (BMI) and total body 
fat7.  The aim of the present paper was to assess the evolution of PTDM during the first year 
after kidney transplantation, and we also hypothesized that there would still be a close 
association between abnormalities in glucose metabolism and VAT measurements, as we 
found at 8-10 weeks after transplantation. The evolution in body composition and VAT 
during the first year post-transplant is  not a a topic in the present study. In addition we 
wanted to assess the associations between glucose metabolism and estimates of insulin 




















PATIENTS AND METHODS 
Study design and population 
The study was a one year follow-up study of patients who received a kidney allograft at our 
transplant center from mid November 2012 to the end of 2013. All patients without known 
diabetes were screened by an oral glucose tolerance test (OGTT) before entering the waiting 
list for transplantation. Figure 1 shows the patient disposition; out of 306 transplanted adult 
patients in the study period, 150 non-diabetic patients had a comprehensive investigation 
performed both 8 (to 10) weeks that was repeated one year after transplantation. This 
investigation included OGTT, DXA scans and measurement of fasting plasma insulin. The 
study was approved by the Regional Ethics Committee for South East Norway and the study 
was performed according to the Helsinki declaration19 and clinical and research activities are 
consistent with the Principles of the Declaration on Istanbul20. All patients signed a written 
informed consent. Demographics and transplant related data for the patient cohort is shown in 
Table 1. This paper presents cross-sectional data for the cohort one year post-transplant. 
 
Glucose tolerance tests and HOMA-indices                                                                            
All the examinations were performed in the morning after an overnight fast. A standard 
OGTT was performed with blood sampling before and 2 hours after oral ingestion of 75 g 
glucose. Glucose metabolism classification was according to ADA criteria for plasma 
glucose21. Normal glucose tolerance (NGT); fasting plasma glucose (fPG)<5.6 mmol/L and 2-
hour plasma glucose (2hPG)<7.8 mmol/L, impaired fasting glucose (IFG); fPG 5.6-5.9 
mmol/L and 2hPG<7.8 mmol/L, impaired glucose tolerance (IGT); fPG<7.0 mmol/L and 
2hPG 7.8-11.0 mmol/L and post transplant diabetes mellitus (PTDM); fPG≥7.0 mmol/L or 
2hPG≥11.1 mmol/L.  
Plasma glucose was measured in fresh venous whole blood using a plasma calibrated 
glucose analyzer (Hemocue® Glucose 201, Ängelholm, Sweden, which fulfills IVD Medical 
Device Directive 98/79/EC)22. Insulin was analyzed with an enzyme-linked immunosorbent 
assay kit (EIA-2935 from DRG® International, Inc., Springfield, New Jersey, USA). The 
homeostatic model assessment-insulin resistance (HOMA-IR) index was used as a measure of 
insulin resistance and calculated from fasting glucose and insulin; HOMA-IR index = (fPG 
(mmol/l) x fInsulin (mU/ml)) / 22.5, and the homeostatic model assessment-beta cell function 
(HOMA-beta) was used as a measure of beta cell function and also calculated from fasting 
glucose and insulin; HOMA-beta = (20 x fInsulin (mU/l)) / (fPG (mmol/l) – 3.5)23,24. 
Creatinine was analyzed with an enzymatic method on Modular P (Roche Diagnostics, 
Pleasanton, CA, USA). All patients were routinely recommended started or continued on 
statin treatment after 3 months post transplant.  
 
Body Composition 
Total body composition was determined by DXA using a narrow fan-beam Lunar Prodigy 
Densitometer (GE Healthcare) and all the scans were analyzed using enCORER software 
version 14.10 (GE Medical Systems, Lunar Corp., Madison, WI)3. Two certified densitometry 
technologists performed all scans. The VAT quantification was manually performed by one 
operator, using the enCORE® software. This operator showed an intra individual coefficient 
of variance < 1% (five repeated measures in twenty patients, data not shown). The enCORE® 
method has been validated against CT, the gold standard7,25. The short- and long-term 
coefficients of variation for our densitometer are 0.8% and 1.4%, respectively. The VAT 
short-term repeat measurement error CV is 9.8%18. 
 
Immunosuppression  
All included patients used oral tacrolimus twice daily (Prograf®, Astellas Pharma US Inc.) 
with an initial dose of 0.04 mg/kg (0.05 mg/kg in high risk patients). High-risk patients were 
defined by panel reactive antibodies >20% and/or presence of donor-specific antibodies. 
Therapeutic drug monitoring was performed from first day after transplantation by measuring 
whole blood trough concentrations. The therapeutic ranges were 3-7 µg/L in standard risk 
patients and 8-12 µg/L in high-risk patients. All patients also received mycophenolate mofetil 
750 mg twice daily and a low-dose steroid protocol. The steroid protocol consisted of 250 mg 
intravenous methylprednisolone on the day of transplantation, followed by oral prednisolone 
(day 1-14: 20 mg/day, day 15-28: 15 mg/day, day 29-60: 10 mg/day, day 61-179: 7.5 mg/day 
and from day 180: 5 mg/day). Patients also received induction therapy with basiliximab (20 
mg on day 0 and 4). High-risk patients received in addition to the above mentioned 
combination also induction therapy with intravenous human immune globulins and rituximab. 
As seen in the flowchart (Figure 1) five eligible patients used cyclosporine. These few 
patients were excluded since the diabetogenic effect may differ between cyclosporine and 
tacrolimus26 27, and we wanted to obtain a most homogenous cohort.  
 
Statistical analyses                                                                                                                   
All statistical analyses were conducted with SPSS version 22. Normal distribution was tested 
by visual inspection on histograms. Pearson Chi-Square and Jonckheere-Terpstra test were 
used as appropriate. CRP was log-transformated before used in linear regression. Descriptive 
data are presented as median with interquartile range (IQR). Univariable and multivariable 
linear regression analyses were used for assessment of association between fasting plasma 
glucose concentration and relevant variables. Variables used in multivariable linear regression 
were chosen based on p-value < 0.25 in univariable linear regression. Collinearity was tested 
by assessing correlations between variables and the tolerance value in the linear regression 









Glucose metabolism improved during the first year after transplantation 
Table 1 shows demographic data, kidney function and immunosuppressive medication for all 
150 transplant recipients stratified for the glucose tolerance groups; NGT (n=81, 54%), IFG 
(n=38, 25%), IGT (n=17, 11%) and PTDM (n=14, 9%) at 1 year post transplant. The glucose 
metabolism was generally improved during the first year, see Figure 2. Patients with PTDM at 
1 year post-transplant were significantly older (p=0.001), had a higher blood trough 
concentration of tacrolimus (P=0.007), and they had a   marginally lower measured 
GFR(p=0.056)) compared to the other glucose tolerance groups. A significantly higher 
proportion of the patients with NGT were females (p=0.017).   
 
Total fat and visceral fat differs between glucose tolerance groups at 1 year after 
transplantation 
Table 2 shows the body composition and glucose metabolism indices for the patients with 
NGT, IFG, IGT and PTDM at 1 year post-transplant. BMI, total body mass, total body fat 
mass and VAT measures were significantly different among the different groups of glucose 
tolerance and the glucose measurements expressed differences between groups as expected. 
Plasma insulin values and HOMA-IR-index were higher with worsening glucose tolerance 
category, while HOMA-beta was lowest in those with PTDM.  
 
Linear regression analyses 
Table 3A shows univariable and multivariable linear regression analysis predicting fasting 
plasma glucose concentration. Recipient age, male gender, BMI, absolute amount VAT, 
VAT%totBFM, total body fat mass, CRP, fasting insulin, HOMA-IR-index and HOMA-beta 
were all independently associated with fasting plasma glucose concentration. Including all 
variables from the univariable linear regression with a p<0.25 (without multicollinearity) 
together into a multivariable model significantly explained 87.4% of the variability in fasting 
plasma glucose concentration (p<0.001). HOMA-IR-index, HOMA-beta, VAT%totBFM and 
BMI were the only significant variables (table 3A). Using backward (p=0.10) and forward 
selection (p=0.05) procedure on the multivariable model, HOMA-IR-index (standardized beta 
1.182, p<0.001), HOMA-beta (standardized beta -1.066, p<0.001), VAT%totBFM (standardized 
beta 0.132, p=0.001) and BMI (standardized beta -0.098, p=0.015) were included variables in 
both procedures, explaining 87.2% of the variability in fasting plasma glucose concentration 
(p<0.001) (not shown in table). Removing BMI from the total model, 86.7% of the variability 
was explained, while removing VAT%totBFM resulted in that 86.6% could be explained – the 
partial R-square for BMI in the model was 0.007, while the partial R-square for VAT%totBFM 
was 0.008. 
Table 3B shows univariable and multivariable linear regression analysis predicting 2-
hour plasma glucose concentration after an OGTT. Univariable linear regression yielded 
recipient age, living donor, absolute amount VAT, VAT%totBFM, blood trough concentration of 
tacrolimus and HOMA-index as significantly associated with 2-hour plasma glucose. 
Inclusion of variables from univariable linear regression with p<0.3 (without 
multicollinearity) in addition to BMI (p=0.575) in a multivariable linear regression model 
explained 31.9% of the variability in 2-hour plasma glucose, with only HOMA-IR index and 
HOMA-beta as significant variables (table 3B). Using backward (p=0.10) and forward 
selection procedure (p=0.05) on the multivariable model, HOMA-IR-index and HOMA-beta 
were the only significant variables with both selection procedures and VAT%totBFM was the 
only other variable included with both selection procedures (but not significant), p<0.001 for 
the total models. Backward regression procedure explained 30.1% of the variability in 2-hour 
plasma glucose concentration (HOMA-IR-index, standardized beta 0.620, p<0.001; HOMA-
beta, standardized beta -0.536, p<0.001; living donor, standardized beta -0.153, p=0.076; BMI 
standardized beta -0.174, p=0.093; VAT%totBFM standardized beta 0.172, p=0.094), while 
forward selection procedure yielded a model explaining 27.3% of the variability in 2-hour 
plasma glucose concentration (HOMA-IR-index, standardized beta 0.569, p<0.001; HOMA-
beta, standardized beta -0.496, p<0.001; blood trough concentration of tacrolimus, 













In the present study, we found a general improvement in glucose metabolism during the first 
year after transplantation and the incidence of PTDM was reduced from 13 to 9%. This 
reversibility of PTDM is in line with findings in previous studies28,29. VAT measures were 
strongly associated with hyperglycemia and PTDM at one year, also in line with our previous 
findingsin kidney transplant patients early after transplantation7. A novel finding in the 
present study was that measures of insulin resistance and insulin release both came out as 
predictors of plasma glucose concentrations. Previous studies have shown conflicting results, 
some favoring insulin release as the major mechanism behind PTDM30, some favoring insulin 
resistance31. Actually insulin release and insulin resistance were both the absolute most robust 
covariates associated with plasma glucose but also VAT%totBFM and BMI contributed 
significantly. In a multivariable linear model a total of 87.4% of the variability in fasting 
plasma glucose concentration could be explained by these variables. Moreover, VAT 
measures were stronger predictors of  both fasting and 2-hour plasma glucose in univariable 
regressions, than BMI. BMI was significantly correlated only with fasting plasma glucose but 
not with 2-hour plasma glucose in our analysis. In multivariable linear regression predicting 
fasting plasma glucose  VAT%totBFM and  BMI were approximately equally important. Neither 
VAT%totBFM nor BMI were significant variables in a multivariable linear model forprediction of 
2-hour plasma glucose concentration, but insulin resistance and beta cell function explained 
31.9% of the variability.  
 One year after transplantation, the absolute amount VAT and VAT%totBFM were 
different among the groups of glucose tolerance.  The VAT measurements were lowest in 
patients with NGT, and highest in patients with PTDM with intermediate values in those with 
IFG and IGT. The same difference was found for insulin resistance and also for CRP, 
although differences in CRP were only borderline significant. Observations in a healthy 
Japanese cohort have also demonstrated an association between VAT and insulin resistance32, 
and a higher state of systemic low-grade inflammation in individuals with higher amount of 
VAT and abdominal fat distribution makes highest values of CRP in patients with PTDM 
expectable33. 
BMI, total body mass and total body fat mass increased according to worsening 
glucose tolerance (higher values in those with IGT than those with IFG, and higher values in 
those with IFG than those with NGT), but actually patients with PTDM seemed to have lower 
or similar median values of BMI and total body fat as those with prediabetes (IFG and IGT). 
A possible explanation for the high VAT%totBFM in patients with PTDM may be hereditary factors 
contributing to obesity and distribution of fat.. Although it is incontestable that obesity results 
from energy intake exceeding energy expenditure, also genetics34,35, hormone secretion 
(steroid hormones, growth hormones) and function of various feedback mechanisms modulate 
both the amount of total body fat and the distribution of fat36. Patients fulfilling criteria for 
PTDM at one year post-transplant might have agenetic predispositionand as suchsusceptible 
for storage of a higher VAT%totBFM. Use of corticosteroids is a known determinant for obesity and 
weight gain after transplantation37, stimulating a more abdominal distribution of fat38. Patients 
with PTDM did not have a higher median daily dosage of prednisolone than the rest of the 
patients, but they had a higher through value of tacrolimus that is known to be diabetogenic39 
According to the World Health Organization BMI 25-29.9 kg/m2 represents 
overweight and BMI > 30 kg/m2 represents obesity40. Our transplant program has set a limit 
of BMI < 30 kg/m2 for kidney recipients due to risk of surgical complications. The BMI 
ranged from 17.6 to 39.1 kg/m2 at one year posttransplant in the present cohort. This limits 
the assessability of BMI as a covariate, but on the other hand it reflects the true clinical 
situation. Anyhow, using BMI > 30 kg/m2 as the definition of obesity also implicates that 
individuals with a high amount of lean mass (muscle) and low fat mass will be categorized as 
obese. This is not favorable when it is the distribution of fat and especially abdominal obesity 
that is the key correlate to the adverse effects of obesity and not BMI41.   
VAT seems to be representative of whole-body adipose tissue dysfunction. As such, 
accumulation of VAT is a consequence of limited storage of fat in peripheral subcutaneous 
adipose tissue, and this limited storage results in energy overflow, lipotoxicity and fatty 
infiltration in non-adipose tissue including visceral accumulation15. Decreasing VAT 
selectively through omentectomy has failed to improve glucose metabolism in obese 
patients42. It is therefore probably more important to reduce whole-body fat dysfunction than 
VAT by itself17. Obesity leads to a dysregulated secretion of adipokines with essential roles 
including regulation of appetite and satiety, distribution of fat, insulin sensitivity and insulin 
secretion. Prophylaxis and treatment of obesity are probably by far the best approach 
including stimulation to physical activity and reduced caloric intake. The importance of 
lifestyle measures for improvement of outcomes in kidney transplant patients is a topic of 
increasing interest. There are some evidence that active lifestyle modifications in these 
patients could improve glucose metabolism43 and a randomized controlled study assessing 
nutrition intervention and exercise has recently been launched44. In our clinic, all patients 
were offered free admittance to training facilities and generally exercise at least 3 times 
weekly during the first 8 weeks after transplantation, and they are encouraged to continue an 
active lifestyle after discharge from the hospital. 
The findings in our study pinpoint the role of VAT in post transplant hyperglycemia 
and PTDM. The study demonstrates that VAT measurements is feasible in larger cohorts of 
patients and allow for future clinical studies on the mechanisms and hopefully treatment 
options of modifiable factors associated with PTDM. It should also be kept in mind that BMI 
and VAT changes over time are not necessarily mirrored.   
  Our study has some limitations. It was restricted to Caucasians and the results may not 
apply to other ethnical groups. The number of patients in each glucose tolerance group was 
limited. We performed OGTT only once, and not twice which is preferable to establish the 
diagnosis of diabetes21. Fewer patients had abnormal 2-hour plasma glucose than fasting 
plasma glucose, possible precluding significant associations in the multivariable linear 
regression predicting 2-hour plasma glucose. Furthermore, the present study is observational 
and we have only demonstrated associations and not causality. 
In conclusion, we have demonstrated an improvement of glucose metabolism one year 
after transplantation and that VAT measurements are strongly associated with hyperglycemia 
one year after kidney transplantation. VAT along with measures of insulin resistance and 
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 Title Legend 
Table 1 Demographic data and body 
composition at one year post-
transplant 
A: Pearson Chi-Square 
B: Jonckheere-Terpstra test for ordered 
alternatives 
Table 2 Comparison of body composition and 
glucose metabolism between patients 
with different glucose tolerance at 
one year post-transplant 
 
A: Pearson Chi-Square 
B: Jonckheere-Terpstra test for ordered 
alternatives 
Table 3A Univariable and multivariable linear 
regression of determinants of fasting 
plasma glucose concentration at one 
year post-transplant 
Unstandardized coefficients refer to 
how many units the dependent variable 
changes per unit change in an 
independent variable. Standardized 
coefficients refer to how many standard 
deviations the dependent variable 
changes per standard deviation change 
in the independent variable, and this 
shows which independent variable has a 
greater effect on the dependent variables  
Table 3B Univariable and multivariable linear 
regression of determinants of 2-hour 
glucose concentration at one year 
post-transplant 
Unstandardized coefficients refer to 
how many units the dependent variable 
changes per unit change in an 
independent variable. Standardized 
coefficients refer to how many standard 
deviations the dependent variable 
changes per standard deviation change 
in the independent variable, and this 
shows which independent variable has a 
greater effect on the dependent variables 
Figure 1 Flowchart of patients included in the 
analysis Only data from one year post-transplant 
is presented in this article, but the 
selection of patients was based on 
patients with registered data from both 
8-weeks and 1 year post transplant. 
 
Figure 2  
Change in glucose tolerance group from 
baseline (measured in a stable phase 8-
10 weeks after transplantation) to 













Figure 1: Flowchart of patients included in the analysis 
 
 
Only data from one year post-transplant is presented in this article, but the selection of patients was 



























Figure 2:  
Total transplantations  
14th of November 2012 - 31th of December 2013 
N = 306 
Patients registered in biobank with blood samples  
at 8 weeks and one year post transplant  
N = 234 
Patients with DXA-scans from 
8 weeks and one year post transplant  
N = 196 
Excluded all patients with registered diabetes mellitus  
before transplantatation 
 (type 1, n=18, type 2, n=28) 
N = 46 
Included 
N = 150 
Patients without relevant DXA-
scans 
N = 38 
Incomplete data for either  
8 week and/or one year posttransplant 
 (n=67), or treated with cyclosporine 
instead of tacrolimus (n=5) 


















































Male gender, n (%) 102 
(68) 
46 (57) 31 (82) 14 (82) 11 (79) 0.017A 
First transplant, n (%) 130 
(87) 
66 (82) 35 (92) 15 (88) 14 (100) 0.168A 
Preemptive transplantation, n (%) 47 (31) 29 (36) 14 (37) 1 (6) 3 (21) 0.070A 
Time in dialysisE , months, median (IQR) 15 (7-
25) 
16 (4-28) 11 (4-23) 17 (10-
23) 
20 (13-33) 0.389B 
Living donor, n (%) 43 (29) 25 (31) 12 (32) 4 (24) 2 (14) 0.576A 
Acute rejection, n (%) 22 (15) 8 (10) 8 (21) 5 (29) 1 (7) 0.097A 
       
























52 (41-64) 0.056B 
       












Prednisolone dose at one year post-transplant, mg/day 5 (5-5) 5 (5-5) 5 (5-5) 5 (5-5) 5 (5-5) 0.986B 
A: Pearson Chi-Square 
B: Jonckheere-Terpstra test for ordered alternatives 
C: GFR was measured based on clearance of a filtration marker and is given in mL/min/1.73m2.  
D: Comparison between glucose tolerance groups 




























Table 2: Comparison of body composition and glucose metabolism between patients in 
different glucose tolerance categories at 1 year post-transplant  
 




















Body composition       








































Visceral fat  (kg), 
median (IQR) 
1.0 (0.5-1.8) 0.9 (0.3-1.4) 1.1 (0.8-2.7) 1.5 (1.2-2.2) 1.5 (0.7-2.1) <0.001* 
Percentage visceral 
fat of total body fat, 
median (IQR) 
4.3 (2.7-6.3) 3.8 (1.6-5.0) 5.7 (3.0-7.3) 5.8 (4.4-7.5) 6.6 (4.6-7.8) <0.001* 




5.4 (5.0-5.9) 5.1 (4.7-5.3) 5.9 (5.7-6.2) 5.9 (5.5-6.3) 7.2 (6.7-7.5) <0.001* 
2 hour plasma 
glucose (mmol/L), 
median (IQR) 
6.1 (5.2-7.1) 5.4 (4.7-6.2) 6.4 (5.4-6.9) 8.3 (8.1-9.0) 13.3 (10.6-
15.2) 
<0.001* 
HbA1c (% glycated 
hemoglobin), median 
(IQR) 
5.8 (5.4-6.1) 5.6 (5.3-5.8) 5.9 (5.6-6.3) 6.0 (5.8-6.3) 6.6 (6.3-7.4) <0.001* 
Fasting insulin 
(pmol/L) , median 
(IQR) 
2.3 (1.6-3.1) 2.1 (1.4-2.9) 2.5 (2.0-3.1) 2.6 (1.8-3.4) 2.7 (2.1-3.6) 0.006* 
Fasting proinsulin 
(pmol/L) , median 
(IQR) 





0.7 (0.4-1.6) 0.8 (0.4-1.8) 0.7 (0.3-1.3) 0.6 (0.3-1.0) 1.0 (0.4-1.9) 0.265 
HOMA-IR-index, 
median (IQR)  









167 (117-215) 101 (73-145) <0.001* 
Systemic 
inflammation 
      
C-reactive protein 
(mg/l), median (IQR) 
1.9 (0.7-4.9) 1.4 (0.7-3.9) 1.9 (0.5-4.8) 2.3 (1.3-5.9) 2.9 (1.4-7.2) 0.085 
A: Pearson Chi-Square 















Table 3A: Univariable and multivariable linear regression of determinants of fasting 
plasma glucose concentration at 1 year post-transplant 
 










Recipient age 0.065 0.013 0.255 0.002* -0.043 0.283 0.874 
Male gender 0.056 0.361 0.238 0.004* 0.003 0.936 
Living donor 0.009 -0.148 -0.095 0.258   
Body mass 
index (kg/m2) 
0.044 0.034 0.209 0.012* -0.104 0.015* 
Visceral fat 
(gram)  
0.140 0.000 0.374 <0.001*   
Total body fat  
(gram) 
0.034 0.000 0.185 0.026*   
% Visceral fat 
of total body 
fat mass 










0.010 0.044 0.099 0.242   
CRP  0.031 0.259 0.127 0.043* -0.015 0.668 
Measured GFR  0.015 -0.006 -0.124 0.189   
Fasting insulin  0.072 0.019 0.269 0.002*   
Proinsulin 0.000 0.004 0.018 0.842   
HOMA-IR-
index  
0.208 0.130 0.456 <0.001* 1.192 <0.001* 
HOMA-beta  0.078 -0.002 -0.279 0.001* -1.077 <0.001* 
Unstandardized coefficients refer to how many units the dependent variable changes per unit change in an independent variable. Standardized 
coefficients refer to how many standard deviations the dependent variable changes per standard deviation change in the independent variable, and this 







Table 3B: Univariable and multivariable linear regression of determinants of 2 hour 
plasma glucose concentration after an OGTT at 1 year post-transplant 
 
 










Recipient age 0.072 0.045 0.268 0.001* 0.037 0.725 0.319 
Male gender 0.013 0.545 0.398 0.172 -0.056 0.602 
Living donor 0.037 -0.950 -0.192 0.020* -0.124 0.153 
Body mass 
index (kg/m2) 
0.002 0.024 0.047 0.575 -0.169 0.110 
Visceral fat 
(gram)  
0.052 0.000 0.228 0.006*   
Total body fat  
(gram) 
0.010 0.000 0.101 0.225   
% Visceral fat 
of total body 
fat mass  










0.031 0.249 0.176 0.036* 0.106 0.250 
CRP  0.004 0.025 0.059 0.501   
Measured GFR  0.020 -0.022 -0.140 0.137 -0.048 0.591 
Fasting insulin  0.017 0.030 0.132 0.125   
Proinsulin 0.000 0.008 0.012 0.892   
HOMA-IR-
index  
0.059 0.217 0.242 0.005* 0.604 <0.001* 
HOMA-beta  0.023 -0.003 -0.151 0.078* -0.492 <0.001* 
Unstandardized coefficients refer to how many units the dependent variable changes per unit change in an independent variable. Standardized 
coefficients refer to how many standard deviations the dependent variable changes per standard deviation change in the independent variable, and this 
shows which independent variable has a greater effect on the dependent variables
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